Juventas Therapeutics Enrolls 1st Patient in Phase 2 Clinical Trial
Juventas Therapeutics, Inc
., a clinical-stage gene therapy company, announced that it is enrolling its STOP-PAD trial, a 120 patient, placebo-controlled, randomized double-blinded Phase 2 study, evaluating the efficacy of JVS-100, a gene therapy encoding human stromal cell-derived factor-1 (SDF-1), in patients with advanced peripheral artery disease (PAD). Dr. John Rundback, Medical Director of the Interventional Institute at Holy Name Medical Center in Teaneck, NJ enrolled the first patient. The trial will recruit additional patients at approximately 25 leading clinical centers in the U.S.
Find Out More About ESP
Contact Mike Bunker for more information